Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 43c, Revenues Beat
July 29, 2019 4:54 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $0.54, $0.43 better than the analyst estimate of $0.11. Revenue for the quarter came in at $183.6 million versus the consensus estimate of $163.14 million.
"Over the past two years, our team has done an excellent job building awareness of tardive dyskinesia within the healthcare community and providing patients... More
